Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
20.56 USD | +4.61% | -7.33% | -12.25% |
05-10 | Akero Therapeutics' Q1 Net Loss Widens; Cash Expected to Fund Operations Into H2 2027 | MT |
05-10 | Akero Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.25% | 1.36B | |
+5.06% | 109B | |
+11.15% | 105B | |
-0.38% | 22.25B | |
-12.12% | 22.09B | |
-7.66% | 18.68B | |
-36.52% | 17.58B | |
-10.03% | 16.85B | |
+3.32% | 13.76B | |
+35.95% | 12.46B |
- Stock Market
- Equities
- AKRO Stock
- News Akero Therapeutics, Inc.
- Canaccord Genuity Adjusts Price Target on Akero Therapeutics to $59 From $58, Maintains Buy Rating